909187-40-2 Usage
General Description
2-fluoro-6-(methylamino)pyridin-3-ylboronic acid is a chemical compound with the molecular formula C6H7BFNO2. It is a boronic acid derivative that contains a pyridine ring with a fluorine atom at position 2 and a methylamino group at position 6. 2-fluoro-6-(methylamino)pyridin-3-ylboronic acid is commonly used as a reagent in organic synthesis and medicinal chemistry, particularly in the development of pharmaceuticals and agrochemicals. Its boronic acid functionality allows for the formation of stable covalent bonds with cis-diols or other Lewis bases, making it a valuable tool in the construction of complex organic molecules. Additionally, the presence of the fluorine and methylamino substituents on the pyridine ring can influence the compound's chemical and biological properties, potentially leading to specific interactions with biological targets. Overall, 2-fluoro-6-(methylamino)pyridin-3-ylboronic acid is a versatile and useful chemical reagent with applications in various fields of research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 909187-40-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,9,1,8 and 7 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 909187-40:
(8*9)+(7*0)+(6*9)+(5*1)+(4*8)+(3*7)+(2*4)+(1*0)=192
192 % 10 = 2
So 909187-40-2 is a valid CAS Registry Number.
909187-40-2Relevant articles and documents
Phthalazine, aza- and diaza-phthalazine compounds and methods of use
-
Page/Page column 49, (2008/06/13)
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
